Accutar Biotechnology Announces FDA Clearance of IND Application for Phase I Trial of AC0176 in Prostate Cancer

By
Justin.choi
-
0
12
Accutar Biotechnology, Inc. announced that the US FDA has cleared the company’s investigational new drug application (IND) for AC0176 for the treatment of patients with metastatic CRPC.
[Accutar Biotechnology, Inc.]

Sorry, but the selected Zotpress account can't be found.

Press Release